Clinical Trials Logo

Clinical Trial Summary

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.


Clinical Trial Description

Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03006003
Study type Interventional
Source Taichung Veterans General Hospital
Contact I-Te Lee, MD, PhD
Phone +886-4-23741300
Email itlee@vghtc.gov.tw
Status Recruiting
Phase Phase 4
Start date January 1, 2017
Completion date December 2021

See also
  Status Clinical Trial Phase
Completed NCT00247429 - Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients Phase 4
Recruiting NCT06104696 - Comprehensive Geriatric Assessment in Kidney Transplantation
Unknown status NCT00229333 - Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Phase 4